ストックスクリーナーアプリを入手
1.41
0.71%
0.01
前日終値:
$1.40
開ける：
$1.43
24時間の取引高:
141.12K
Relative Volume:
0.68
時価総額：
$31.67M
収益：
-
当期純損益:
$-55.99M
株価収益率:
-0.5637
EPS:
-2.5013
ネットキャッシュフロー:
$-47.60M
1週間 パフォーマンス:
+0.71%
1か月 パフォーマンス:
-5.37%
6か月 パフォーマンス:
+23.68%
1年 パフォーマンス:
+29.36%
1日の値動き範囲:
$1.40
$1.44
1週間の範囲:
$1.38
$1.45
52週間の値動き範囲:
$0.9612
$1.68
Boundless Bio Inc Stock (BOLD) Company Profile
Compare BOLD vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.41 | 31.45M | 0 | -55.99M | -47.60M | -2.5013 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-05-28 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-12-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-04-22 | 開始されました | Guggenheim | Buy |
| 2024-04-22 | 開始されました | Leerink Partners | Outperform |
| 2024-04-22 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Boundless Bio Inc (BOLD) 最新ニュース
Boundless Bio (BOLD) director receives grant of 32,000 stock options at $1.40 - Stock Titan
Director Jonathan Lim gets 48,000 Boundless Bio (BOLD) options at $1.40 strike - Stock Titan
[Form 4] Boundless Bio, Inc. Insider Trading Activity - Stock Titan
Boundless Bio director granted 32,000 options | BOLD Insider Trading - Stock Titan
SpaceX Sets $75 Billion IPO Record Ahead of Nasdaq DebutNext Quarter Guidance - newsline.com
BOLD Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
MTUS Q1 2026 Earnings: EPS Surpasses Estimates by 17.65%Short-Term Outlook - newsline.com
VSNT Q1 2026 Earnings: EPS Surges Past Estimates, Stock Moves HigherProfit Guidance Range - newsline.com
BOLD Q1 2026 Earnings: Wider-Than-Expected Loss in Pre-Revenue Phase; Stock Holds Steady - newsline.com
Boundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLD - TipRanks
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Jack In The Box (JACK) Nears Critical Support After 2.83% DeclineBox Spread - newsline.com
Rallybio finds a new reverse-merger dance partner in Avenzo - FirstWord Pharma
Nio Launches First Flagship EV in Two Years, Shares Surge on ES9 SUV DebutForward EPS Estimate - newsline.com
Boundless Bio Inc. (BOLD) Holds Near Support Amid Modest DeclineDividend ETF - The Legal Advocate
ASBA Q1 2026 Earnings: EPS Beats Estimates, Stock Edges HigherRevenue Per Share - newsline.com
AMZN Q1 2026 Earnings: EPS Misses Estimates by 3.6% as Stock Climbs 0.79%Guidance Downgrade Alert - The Legal Advocate
RenovoRx Inc. (RNXT) Moves Higher by 6.2% as Shares Approach Resistance at $1.04Breadth Thrust - The Legal Advocate
Amazon's AI Strategy Sets It Apart from Big Tech Rivals: Focus on Cloud and EnterpriseRevenue Guidance Update - newsline.com
Amer Sports Q1 2026 Earnings: EPS Beats Estimates by 21.1%, Revenue Not DisclosedEarnings Trend Analysis - newsline.com
OM Q1 2026 Earnings: EPS Misses Estimates as Outset Medical Posts Wider-Than-Expected Loss; Stock Edges Up - newsline.com
BBAI Q1 2026 Earnings: AI Specialist Reports Wider Loss, Revenue Data UnavailableEarnings Revision Upgrade - thelegaladvocate.com
Trump Shielded From IRS Audits as Expanded Settlement Deal Draws ScrutinyNet Income Trends - The Legal Advocate
Spyre Therapeutics (SYRE) Stock: Down -2.00%, Support Test at $70.43 2026-05-15Wave Alternation - newsline.com
ZYXI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
RLYB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TradingKey - TradingKey
Number of shareholders of Boundless Bio, Inc. – NASDAQ:BOLD - TradingView
BOLD: ecDNA-targeted therapies offer a novel approach for hard-to-treat oncogene amplified cancers - TradingView
Boundless Bio Releases Q1 2026 Financial Results - AlphaStreet
Boundless Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Boundless Bio, Inc. 1Q 2026: Net income $(13.6)M, EPS $(0.60) — 10-Q Summary - TradingView
Boundless Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Boundless Bio (NASDAQ: BOLD) trims spend, ends HQ lease, guides cash into 2H 2028 - Stock Titan
Boundless Bio (Nasdaq: BOLD) Q1 2026 results and $92.8M cash runway - Stock Titan
Boundless Bio 1Q Loss/Shr 60c >BOLD - Moomoo
Cancer drug trial keeps enrolling as Boundless Bio says cash lasts to 2028 - Stock Titan
RE/MAX Holdings Releases Q1 2026 Financial Results - AlphaStreet
What BoundlessBio (BOLD) is doing that smart investors recognize (Breakout Watch) 2026-05-06Crowd Sentiment Stocks - newser.com
Boundless Bio Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
How Hudson (HPP) talent strategy drives results | Q4 2025: Profit DisappointsEPS Surprise History - The Legal Advocate
[ARS] Boundless Bio, Inc. SEC Filing - Stock Titan
Boundless Bio (NASDAQ: BOLD) details 2026 virtual meeting and pay - Stock Titan
BOLD | Boundless Bio, Inc. Common Insider Trading - Quiver Quantitative
CIIT (Tianci Intl) falls 5.75% after Q1 2026 earnings release reporting negative $1.19 earnings per share.Restructuring - Xã Vĩnh Công
BOLD (Boundless Bio Inc.) falls 3.07% following wider-than-expected Q4 2025 earnings per share miss.Days To Cover - Xã Thanh Hà
MIAX Miami reports strong Q4 2025 earnings, 24 percent EPS beat pushes shares up 2.4 percent.Margin Expansion Trends - The Legal Advocate
OGI (Organigram Global Inc. Common Shares) delivers blowout Q1 2026 results with 62 percent annual revenue growth and positive earnings.Dividend Safety - Cổng thông tin điện tử tỉnh Lào Cai
BoundlessBio (BOLD) Stock: Technical Trend Review | Boundless Bio Inc. misses EPS estimates by 9.4% on wider lossesPEG Ratio - Cổng thông tin điện tử tỉnh Lào Cai
Quest Diagnostics (DGX)Evolving Investment Narrative Amid Mixed Analyst Target Adjustments and Operational Growth CatalystsMid-Term Outlook - newsline.com
BoundlessBio (BOLD) Stock Top Holdings (-0.32%) 2026-04-20Hot Community Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Boundless Bio Inc (BOLD) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):